SARS-CoV-2-Vaccine-Related Endocrine Disorders: An Updated Narrative Review

Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 750 - 750

Published: July 8, 2024

The emergence of the COVID-19 pandemic has led to rapid and worldwide development investigation multiple vaccines. While most side effects these vaccines are mild transient, potentially severe adverse events may occur involve endocrine system. This narrative review aimed explore current knowledge on potential following vaccination, with thyroid disorders being common. Data about pituitary, adrenal, diabetes, gonadal also reviewed. provides a comprehensive understanding pathogenesis associated SARS-CoV-2 PubMed/MEDLINE, Embase database (Elsevier), Google Scholar searches were performed. Case reports, case series, original studies, reviews written in English published online up 31 August 2023 selected accumulating. However, their causal relationship is not strong enough make definite conclusion, further studies needed clarify mechanisms linked

Language: Английский

---

Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1270 - 1270

Published: Nov. 11, 2024

Although immune checkpoint inhibitors (ICIs) have become predominant therapies for cancer, the safety and efficacy of combining ICIs with vaccinations remain areas needed investigation. As gain broader clinical application, relevance current vaccination guidelines cancer patients-largely developed in context cytotoxic therapies-becomes increasingly uncertain. data support inactivated influenza mRNA SARS-CoV-2 vaccines ICI therapy, comprehensive on other infectious disease scarce. Notably, combination does not appear to exacerbate immune-related adverse events, despite heightened cytokine activity observed. However, administered alongside preventing diseases remains poorly supported by robust evidence. Preliminary findings suggest a potential survival benefit patients receiving therapy or vaccination, though quality evidence is currently low. Moreover, synergistic therapeutic vaccines, particularly mRNA-based indicates promise but paucity phase III confirm efficacy. This review critically examines both vaccines. While appears safe undergoing impact prevention treatment outcomes warrants further rigorous

Language: Английский

---

Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population

Asia-Pacific Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 20(3), P. 379 - 385

Published: Jan. 14, 2024

Abstract Background Cancer patients have increased morbidity and mortality from COVID‐19, but may respond poorly to vaccination. The Evaluation of COVID‐19 Vaccination Efficacy Rare Events in Solid Tumors (EVEREST) study, comparing seropositivity between cancer healthy controls a low SARS‐CoV‐2 community‐transmission setting, allows determination vaccine response with minimal interference infection. Methods tumor Canberra Hospital, Canberra, Australia, who received vaccination March 2021 January 2022 were included. Blood samples collected at baseline, pre‐second dose 1, 3 (primary endpoint), 6 months post‐second dose. anti‐spike‐RBD (S‐RBD) anti‐nucleocapsid IgG antibodies measured. Results Ninety‐six solid 20 enrolled, median age 62 years, 60% female. Participants either AZD1222 (65%) or BNT162b2 (35%) vaccines. Seropositivity post was 87% (76/87) 100% (20/20) ( p = .12). observed 84% on chemotherapy, 80% immunotherapy, 96% targeted therapy (differences not satistically significant). 40% (6/15) after first dose, 95% (35/37) 1 month second then dropped Conclusion Most all became seropositive two doses. Antibody concentrations showed decrease vaccination, highlighting need for booster vaccinations. infection amplifies S‐RBD antibody responses; however, cannot be adequately identified using nucleocapsid serology. This underlines the value our COVID‐naïve population studying immunogenicity.

Language: Английский

---

COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study

Infectious Agents and Cancer, Journal Year: 2023, Volume and Issue: 18(1)

Published: Sept. 7, 2023

Abstract Background Coronavirus disease 2019 (COVID-19) vaccine has played a major role in ending the pandemic. However, little is known about influence of COVID-19 on efficacy immunotherapy patients with non-small cell lung cancer (NSCLC). Objectives The goal this study to explore whether impacts immune checkpoint inhibitors (ICIs) NSCLC patients. Methods We retrospectively analyzed survival data ICI-treated 104 stage III–IV NSCLC, who either received vaccination (n = 25) or no 79). potential risk factors, particular roles ICIs these patients, were evaluated. Results Our results showed significantly improved ORR (28.0% vs. 11.39%, p 0.05) and DCR (88.0% 54.43%, 0.005) vaccinated group compared non-vaccinated group. Regarding long-term benefits, profound both PFS (HR 0.16, 0.021) OS 0.168, 0.019) under treatment. ( < 0.001) was group, Moreover, CD4 T 0.047) level higher than Conclusions enhances anti-PD-1 suggesting that may provide additional benefit

Language: Английский

---

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Cancers, Journal Year: 2023, Volume and Issue: 15(19), P. 4777 - 4777

Published: Sept. 28, 2023

In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; 935) vaccinated against COVID-19, we noticed the following: i/after vaccination, 4.4% HCWs 5.8% CP were infected; ii/no characteristic was associated with post-vaccine COVID-19 infections among HCWs; iii/CP who developed younger, more frequently women (NS), had gastrointestinal, gynecological, or breast localized stage; iv/CP while receiving chemotherapy targeted therapy (NS) breakthrough after vaccination than those these treatments; opposite noted radiotherapy, immunotherapy, hormonotherapy; v/most occurred either during Alpha wave (11/41 HCW, 20/49 CP), early first campaign started, Omicron (21/41 3 months second dose; vi/risk infection not values antibody titers; vii/the outcome severe in all cases. To conclude, around 5% our CPs despite previous vaccination. The severe.

Language: Английский

---

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(11), P. e0310781 - e0310781

Published: Nov. 7, 2024

The aim of this study was to assess the seroconversion rate and percent inhibition neutralizing antibodies against wild-type Omicron variants SARS-CoV-2 in patients with solid cancer who received two COVID-19 vaccine doses by comparing chemotherapy nonchemotherapy groups.

Language: Английский

---

Progress in modifying and delivering mRNA therapies for cancer immunotherapy

Advances in immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---

Cancer bronchopulmonaire

Revue des Maladies Respiratoires Actualités, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---

Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?

Revue des Maladies Respiratoires Actualités, Journal Year: 2023, Volume and Issue: 15(2), P. 2S209 - 2S213

Published: Oct. 1, 2023

---